Zobrazeno 1 - 10
of 288
pro vyhledávání: '"Ronenn Roubenoff"'
Autor:
Lynn Rochester, Claudia Mazzà, Arne Mueller, Brian Caulfield, Marie McCarthy, Clemens Becker, Ram Miller, Paolo Piraino, Marco Viceconti, Wilhelmus P. Dartee, Judith Garcia-Aymerich, Aida A. Aydemir, Beatrix Vereijken, Valdo Arnera, Nadir Ammour, Michael Jackson, Tilo Hache, Ronenn Roubenoff
Publikováno v:
Digital Biomarkers, Vol 4, Iss 1, Pp 13-27 (2020)
Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes
Externí odkaz:
https://doaj.org/article/f96df154fed741b29e9fc9cb86f7daf3
Autor:
Joanna Brzeszczyńska, Angelika Meyer, Robin McGregor, Alain Schilb, Simone Degen, Valentina Tadini, Neil Johns, Ramon Langen, Annemie Schols, David J. Glass, Ronenn Roubenoff, James A. Ross, Kenneth C.H. Fearon, Carolyn A. Greig, Carsten Jacobi
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 9, Iss 1, Pp 93-105 (2018)
Abstract Background Sarcopenia is defined as the age‐related loss of skeletal muscle mass and function. While all humans lose muscle with age, 2–5% of elderly adults develop functional consequences (disabilities). The aim of this study was to inv
Externí odkaz:
https://doaj.org/article/c09f7a587c5642489648c9ba03775860
Autor:
Neil Johns, Shinji Hatakeyama, Nathan A Stephens, Martin Degen, Simone Degen, Wilfried Frieauff, Christian Lambert, James A Ross, Ronenn Roubenoff, David J Glass, Carsten Jacobi, Kenneth C H Fearon
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e83618 (2014)
BACKGROUND: Cachexia affects the majority of patients with advanced cancer and is associated with a reduction in treatment tolerance, response to therapy, and duration of survival. One impediment towards the effective treatment of cachexia is a valid
Externí odkaz:
https://doaj.org/article/137790f226e44fdeb5933e061427f34e
Autor:
Heming Xing, Paul D McDonagh, Jadwiga Bienkowska, Tanya Cashorali, Karl Runge, Robert E Miller, Dave Decaprio, Bruce Church, Ronenn Roubenoff, Iya G Khalil, John Carulli
Publikováno v:
PLoS Computational Biology, Vol 7, Iss 3, p e1001105 (2011)
Tumor necrosis factor α (TNF-α) is a key regulator of inflammation and rheumatoid arthritis (RA). TNF-α blocker therapies can be very effective for a substantial number of patients, but fail to work in one third of patients who show no or minimal
Externí odkaz:
https://doaj.org/article/d80bf7a0804f4a0aad4ebd11b36730c2
Autor:
Didier Laurent, Jon Riek, Christopher D.J. Sinclair, Parul Houston, Ronenn Roubenoff, Dimitris A. Papanicolaou, Attila Nagy, Steve Pieper, Tarek A. Yousry, Michael G. Hanna, John S. Thornton, Pedro M. Machado
Publikováno v:
Neurology. 99:e865-e876
Background and ObjectivesLimited data suggest that quantitative MRI (qMRI) measures have potential to be used as trial outcome measures in sporadic inclusion body myositis (sIBM) and as a noninvasive assessment tool to study sIBM muscle pathologic pr
Autor:
Olivier Petricoul, Arman Nazarian, Uwe Schuehly, Ursula Schramm, Olivier J. David, Didier Laurent, Jens Praestgaard, Ronenn Roubenoff, Dimitris A. Papanicolaou, Daniel Rooks
Publikováno v:
Clinical pharmacokinetics.
Bimagrumab is a human monoclonal antibody binding to the activin type II receptor with therapeutic potential in conditions of muscle wasting and obesity. This phase I study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), and safety of var
Autor:
David Demanse, Franziska Saxer, Patrick Lustenberger, László B. Tankó, Philipp Nikolaus, Ilja Rasin, Damian F. Brennan, Ronenn Roubenoff, Sumehra Premji, Philip G Conaghan, Matthias Schieker
Publikováno v:
Seminars in Arthritis and Rheumatism. 58:152140
Osteoarthritis (OA) is a complex disease comprising diverse underlying patho-mechanisms. To enable the development of effective therapies, segmentation of the heterogenous patient population is critical. This study aimed at identifying such patient c
Autor:
Jens Praestgaard, Ronenn Roubenoff, Olivier Petricoul, Didier Laurent, Daniel Rooks, Michael Bartlett
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle
Background Bimagrumab prevents activity of myostatin and other negative regulators of skeletal muscle mass. This randomized double-blind, placebo-controlled study investigated safety, pharmacokinetics (PK), and pharmacodynamics of bimagrumab in healt
Autor:
Paul M. Ridker, Ronenn Roubenoff, Jens Praestgaard, Daniel H. Solomon, Linda Mindeholm, Herman Gram, Philip G. Conaghan, C. Scotti, Tom Thuren, Matthias Schieker
Publikováno v:
Ann Intern Med
Background: Osteoarthritis is a common inflammatory disorder with no disease-modifying therapies. Whether inhibition of interleukin-1β (IL-1β) can reduce the consequences of large joint osteoarthritis is unclear. Objective: To determine whether IL-
Biomedical research accuracy and relevance for improving healthcare are increasingly identified as costly problems. Basic research data quality, reporting and methodology, and reproducibility are common factors implicated in this challenge. Preclinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37f59765d1a48d34a90cff8605823fb6
https://zenodo.org/record/6044233
https://zenodo.org/record/6044233